BHB supplement with CAR-T for lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have been diagnosed with large B-cell lymphoma (a type of blood cancer)
- You plan to receive one of the standard CAR-T therapies called Yescarta or Kymriah
- You are not allergic to energy drinks
- You do not have inflammatory bowel disease or type 1 diabetes, and your kidneys work well enough (a GFR of 30 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a natural metabolite called beta-hydroxybutyrate can strengthen CAR-T cell therapy (a type of cancer-fighting cell treatment) in multiple myeloma patients. The goal is to help your immune cells work better against your cancer.
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
This study tests a customized cancer treatment called CD19 CAR-T for people newly diagnosed with certain high-risk large B-cell lymphoma. It aims to see whether this treatment can help control the lymphoma, especially in higher-risk cases.
This trial tests combining an experimental drug (CLS-015) with a standard CAR-T cell therapy for people with large B-cell lymphoma whose disease is stable or progressing. It aims to see if the combination is safe and might improve treatment outcomes.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.